

**Study Number:** I94043

**Test Type:** TOX

**Route:** Dosing in Water

**Species/Strain:** Mouse/B6C3F1/N

**PA10X: Statistical Analysis of Non-Neoplastic Lesions**

**Test Compound:** Sodium Metavanadate

**CAS Number:** 13718-26-8

**Date Report Requested:** 09/15/2020

**Time Report Requested:** 11:00:43

**Lab:** Burleson Research Technologies

**Study Number:**

I94043

**Study Gender:**

Female

**PWG Approval Date:**

See web page for date of PWG Approval

**Version:**

v1.0.5

Study Number: I94043  
 Test Type: TOX  
 Route: Dosing in Water  
 Species/Strain: Mouse/B6C3F1/N

PA10X: Statistical Analysis of Non-Neoplastic Lesions  
 Test Compound: Sodium Metavanadate  
 CAS Number: 13718-26-8

Date Report Requested: 09/15/2020  
 Time Report Requested: 11:00:43  
 Lab: Burlison Research Technologies

Female : Immunopath

	Treatment Groups (ppm)					
	0	31.3	62.5	125	250	500
<b>Disposition Summary</b>						
Animals Initially In Study	8	8	8	8	8	8
Early Deaths						
Scheduled Deaths						
Scheduled sacrifice, terminal (SD 28)	8	8	8	8	8	8
Number of Animals Examined	8	8	8	8	8	8
<b>ALIMENTARY SYSTEM</b>						
LIVER	(8)	(8)	(8)	(8)	(8)	(8)
INFLAMMATION; FOCAL	8 (100%)	8 (100%)	8 (100%)	8 (100%)	8 (100%)	8 (100%)
<b>CARDIOVASCULAR SYSTEM</b>						
None						
<b>ENDOCRINE SYSTEM</b>						
ADRENAL GLAND, RIGHT	(8)	(8)	(8)	(8)	(8)	(8)
HYPERPLASIA; SUBCAPSULAR	4 (50%)	6 (75%)	8 (100%) *	6 (75%)	6 (75%)	8 (100%) *
<b>GENERAL BODY SYSTEM</b>						
None						
<b>GENITAL SYSTEM</b>						
None						
<b>HEMATOLYMPHOID SYSTEM</b>						
SPLEEN	(8)	(8)	(8)	(8)	(8)	(8)
RED PULP; EXTRAMEDULLARY HEMATOPOEISIS; INCREASED	1 (12.5%)					
THYMUS	(8)	(8)	(8)	(8)	(8)	(8)
CYST		2 (25%)	2 (25%)	4 (50%) *	1 (12.5%)	

Study Number: I94043

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Test Compound: Sodium Metavanadate

CAS Number: 13718-26-8

Date Report Requested: 09/15/2020

Time Report Requested: 11:00:43

Lab: Burleson Research Technologies

Female : Immunopath

Treatment Groups (ppm)

0 31.3 62.5 125 250 500

INTEGUMENTARY SYSTEM

None

MUSCULOSKELETAL SYSTEM

None

NERVOUS SYSTEM

None

RESPIRATORY SYSTEM

LUNG	(8)	(8)	(8)	(8)	(8)	(8)
CONGESTION			1 (12.5%)			
INTERSTITIUM; INFILTRATE, CELLULAR; MIXED	1 (12.5%)		1 (12.5%)	1 (12.5%)	1 (12.5%)	
INFILTRATE, CELLULAR; HISTIOCYTE			1 (12.5%)			

SPECIAL SENSES SYSTEM

None

URINARY SYSTEM

KIDNEY, RIGHT	(8)	(8)	(8)	(8)	(8)	(8)
INTERSTITIUM; INFILTRATE, CELLULAR; MIXED				2 (25%)		
PELVIS; INFILTRATE, CELLULAR; MIXED	4 (50%)	7 (87.5%)	7 (87.5%)	7 (87.5%)	3 (37.5%)	4 (50%)

**Study Number:** I94043  
**Test Type:** TOX  
**Route:** Dosing in Water  
**Species/Strain:** Mouse/B6C3F1/N

**PA10X: Statistical Analysis of Non-Neoplastic Lesions**  
**Test Compound:** Sodium Metavanadate  
**CAS Number:** 13718-26-8

**Date Report Requested:** 09/15/2020  
**Time Report Requested:** 11:00:43  
**Lab:** Burleson Research Technologies

## LEGEND

---

Number of animals examined for each tissue shown in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical significance is found for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number of animals with observation reported with percent incidence in parentheses

Statistical analysis performed by Cochran-Armitage (trend) and Fisher Exact (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

All trend and pairwise p-values are reported as one-sided.

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

**\*\* END OF REPORT \*\***